Peng, Liang <br/><br/>
A novel scoring model to predict benefit of additional induction chemotherapy to concurrent chemoradiotherapy in stage II-IVa nasopharyngeal carcinoma.  [electronic resource] 

 -  Oral oncology  11 2018 
 - 258-265 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-0593 
<br/><br/><label>Standard No.: </label>10.1016/j.oraloncology.2018.10.007  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Cell-Free Nucleic Acids--blood<br/>Chemoradiotherapy--methods<br/>Clinical Decision-Making--methods<br/>DNA, Viral--blood<br/>Disease-Free Survival<br/>Epstein-Barr Virus Infections--mortality<br/>Female<br/>Follow-Up Studies<br/>Herpesvirus 4, Human--genetics<br/>Humans<br/>Induction Chemotherapy--methods<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Models, Biological<br/>Nasopharyngeal Carcinoma--mortality<br/>Nasopharyngeal Neoplasms--mortality<br/>Neoplasm Staging<br/>Patient Selection<br/>Prognosis<br/>Proportional Hazards Models<br/>Retrospective Studies